These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31689604)

  • 21. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
    Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
    Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.
    Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Monte E; Pérez-Alenda S; Bosch P; Querol F; Poveda JL
    Thromb Res; 2019 Feb; 174():151-162. PubMed ID: 30634166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
    Katragadda S; Neelakantan S; Diao L; Wong N
    J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.
    Elm T; Karpf DM; Øvlisen K; Pelzer H; Ezban M; Kjalke M; Tranholm M
    Haemophilia; 2012 Jan; 18(1):139-45. PubMed ID: 21771205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].
    Hua BL; Chelle P; Yeung C; Gu J; Zhao YQ; Iorio A
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):673-677. PubMed ID: 31495135
    [No Abstract]   [Full Text] [Related]  

  • 28. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.
    McEneny-King A; Chelle P; Foster G; Keepanasseril A; Iorio A; Edginton AN
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):411-426. PubMed ID: 31104228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.
    Ragni MV; Malec LM
    Expert Rev Hematol; 2014 Dec; 7(6):747-55. PubMed ID: 25374055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.
    McMullen S; Buckley B; Hall E; Kendter J; Johnston K
    Value Health; 2017 Jan; 20(1):93-99. PubMed ID: 28212975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate
    Chelle P; Yeung CHT; Croteau SE; Lissick J; Balasa V; Ashburner C; Park YS; Bonanad S; Megías-Vericat JE; Nagao A; Wynn T; Corrales-Medina F; Tran H; Sharathkumar A; Chitlur M; Sarmiento S; Edginton A; Iorio A
    Clin Pharmacokinet; 2020 Feb; 59(2):245-256. PubMed ID: 31435896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?
    Allard Q; Djerada Z; Pouplard C; Repessé Y; Desprez D; Galinat H; Frotscher B; Berger C; Harroche A; Ryman A; Flaujac C; Chamouni P; Guillet B; Volot F; Szymezak J; Nguyen P; Cazaubon Y
    Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32326156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
    Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
    Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.
    Blanchette VS; Zunino L; Grassmann V; Barnes C; Carcao MD; Curtin J; Jackson S; Khoo L; Komrska V; Lillicrap D; Morfini M; Romanova G; Stephens D; Zapotocka E; Rand ML; Blatny J
    Thromb Haemost; 2021 Oct; 121(10):1326-1336. PubMed ID: 33506480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
    Mingot-Castellano ME; Parra R; Núñez R; Martorell M
    Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A longer acting rFVIII, safe and effective.
    Lusher JM
    Blood; 2014 Jan; 123(3):304-5. PubMed ID: 24434992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.